Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1
Cosmos Health (NASDAQ:COSM) has announced it will not proceed with its planned offering under Form S-1 until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The company, which operates as a diversified healthcare group focusing on pharmaceutical and nutraceutical brands, manufacturing, distribution, and telehealth services, has postponed any potential offering until after the annual financial reporting is complete.
Cosmos Health (NASDAQ:COSM) ha annunciato che non procederà con l'offerta pianificata ai sensi del Modulo S-1 fino a dopo la presentazione del suo Rapporto Annuale sul Modulo 10-K per l'anno fiscale chiuso il 31 dicembre 2024. L'azienda, che opera come un gruppo sanitario diversificato focalizzato su marchi farmaceutici e nutraceutici, produzione, distribuzione e servizi di telemedicina, ha rinviato qualsiasi offerta potenziale fino al completamento della rendicontazione finanziaria annuale.
Cosmos Health (NASDAQ:COSM) ha anunciado que no procederá con su oferta planificada bajo el Formulario S-1 hasta después de presentar su Informe Anual en el Formulario 10-K para el año fiscal que terminó el 31 de diciembre de 2024. La empresa, que opera como un grupo de atención médica diversificado centrado en marcas farmacéuticas y nutracéuticas, fabricación, distribución y servicios de telemedicina, ha pospuesto cualquier oferta potencial hasta que se complete la presentación de informes financieros anuales.
코스모스 헬스 (NASDAQ:COSM)는 2024년 12월 31일 종료된 회계연도에 대한 10-K 양식 연례 보고서를 제출한 후에야 S-1 양식에 따른 계획된 공모를 진행하지 않을 것이라고 발표했습니다. 제약 및 건강기능식품 브랜드, 제조, 유통 및 원격의료 서비스를 중심으로 운영되는 다각화된 의료 그룹인 이 회사는 연례 재무 보고가 완료될 때까지 잠재적인 공모를 연기했습니다.
Cosmos Health (NASDAQ:COSM) a annoncé qu'il ne procédera pas à son offre prévue sous le formulaire S-1 avant d'avoir déposé son rapport annuel sur le formulaire 10-K pour l'exercice clos le 31 décembre 2024. L'entreprise, qui opère en tant que groupe de santé diversifié axé sur les marques pharmaceutiques et nutraceutiques, la fabrication, la distribution et les services de télémédecine, a reporté toute offre potentielle jusqu'à ce que le reporting financier annuel soit complet.
Cosmos Health (NASDAQ:COSM) hat bekannt gegeben, dass es sein geplantes Angebot gemäß Formular S-1 bis nach der Einreichung seines Jahresberichts im Formular 10-K für das am 31. Dezember 2024 endende Geschäftsjahr nicht fortsetzen wird. Das Unternehmen, das als diversifizierte Gesundheitsgruppe tätig ist und sich auf pharmazeutische und nutraceutical Marken, Herstellung, Vertrieb und Telemedizin-Dienste konzentriert, hat jegliches potenzielle Angebot bis nach Abschluss der jährlichen Finanzberichterstattung verschoben.
- Delayed offering prevents immediate shareholder dilution
- Potential delay in raising capital through S-1 offering
- Company may need to postpone planned business initiatives requiring additional funding
Insights
This strategic pause in Cosmos Health's S-1 offering process carries significant implications for both the company and its shareholders. The decision to wait until after the 10-K filing suggests a deliberate approach to transparency and timing in the capital markets. This move is particularly noteworthy for a micro-cap healthcare company with a market capitalization of just
The delay likely serves multiple strategic purposes. First, it allows potential investors to evaluate the company's complete 2024 financial performance before making investment decisions. Second, it may indicate management's desire to potentially secure better offering terms based on their full-year results. However, this postponement could also signal near-term liquidity management challenges, as companies typically pursue S-1 offerings to raise capital.
For existing shareholders, this development has mixed implications. While the delay temporarily prevents immediate dilution, it also raises questions about the company's current capital needs and financing strategy. The timing of this announcement, coming near the fiscal year-end, suggests a calculated decision to align capital raising efforts with the comprehensive financial disclosure in the upcoming 10-K.
The healthcare sector, particularly in the micro-cap segment, often requires substantial capital for R&D, product development, and market expansion. This pause in the offering process may affect Cosmos Health's ability to execute its growth initiatives in the near term, potentially impacting its competitive position in the vertically integrated healthcare space.
CHICAGO, IL / ACCESS Newswire / February 18, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
Why did Cosmos Health (COSM) postpone its Form S-1 offering?
When will COSM proceed with its planned offering?
What is the impact of COSM's delayed S-1 offering on shareholders?
When will COSM file its 2024 Annual Report on Form 10-K?
